Commonly mutated gene could be a therapeutic target in sarcoma

Medical Xpress - latest medical and health news stories ·
Health & Medicine United Kingdom

Researchers at The University of Texas MD Anderson Cancer Center have discovered that sarcomas lacking the ATRX gene tend to be more aggressive and may be particularly vulnerable to a class of targeted therapies known as TEAD inhibitors. The findings identify ATRX loss as both a marker of poor prognosis and a potential therapeutic target.

Read original article on Medical Xpress - latest medical and health news stories →